

# Gaia Nebbia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5996018/publications.pdf>

Version: 2024-02-01

12  
papers

1,612  
citations

1305906

8  
h-index

1336881

12  
g-index

19  
all docs

19  
docs citations

19  
times ranked

5393  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 infection early in the pandemic and the role of unidentified cases in transmission. <i>Clinical Microbiology and Infection</i> , 2022, 28, 93-100.	2.8	21
2	Descriptive comparison of admission characteristics between pandemic waves and multivariable analysis of the association of the Alpha variant (B.1.1.7 lineage) of SARS-CoV-2 with disease severity in inner London. <i>BMJ Open</i> , 2022, 12, e055474.	0.8	12
3	VirA+EmiC project: Evaluating real-world effectiveness and sustainability of integrated routine opportunistic hepatitis B and C testing in a large urban emergency department. <i>Journal of Viral Hepatitis</i> , 2022, 29, 559-568.	1.0	7
4	Protocol for the COG-UK hospital-onset COVID-19 infection (HOCl) multicentre interventional clinical study: evaluating the efficacy of rapid genome sequencing of SARS-CoV-2 in limiting the spread of COVID-19 in UK NHS hospitals. <i>BMJ Open</i> , 2022, 12, e052514.	0.8	12
5	SARS-CoV-2 lineage B.1.1.7 is associated with greater disease severity among hospitalised women but not men: multicentre cohort study. <i>BMJ Open Respiratory Research</i> , 2021, 8, e001029.	1.2	22
6	The Alpha variant was not associated with excess nosocomial SARS-CoV-2 infection in a multi-centre UK hospital study. <i>Journal of Infection</i> , 2021, 83, 693-700.	1.7	11
7	Translational Research in the Time of COVID-19 – Dissolving Boundaries. <i>PLoS Pathogens</i> , 2020, 16, e1008898.	2.1	7
8	Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. <i>Nature Microbiology</i> , 2020, 5, 1598-1607.	5.9	1,115
9	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. <i>PLoS Pathogens</i> , 2020, 16, e1008817.	2.1	105
10	An Economic Evaluation of the Cost-Effectiveness of Opt-Out Hepatitis B and Hepatitis C Testing in an Emergency Department Setting in the United Kingdom. <i>Value in Health</i> , 2020, 23, 1003-1011.	0.1	22
11	Real-world evaluation of a novel technology for quantitative simultaneous antibody detection against multiple SARS-CoV-2 antigens in a cohort of patients presenting with COVID-19 syndrome. <i>Analyst</i> , 2020, 145, 5638-5646.	1.7	26
12	An innovative approach to increase viral hepatitis diagnoses and linkage to care using opt-out testing and an integrated care pathway in a London Emergency Department. <i>PLoS ONE</i> , 2018, 13, e0198520.	1.1	20